Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of Pimasertib in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed solid tumors, either refractory to standard therapy or for which no effective standard therapy is available, with a measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~* An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to (\<=) 1~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Disease conditions or concomitant medication that may significantly influence the conduct of the trial or an abnormal electrocardiogram (ECG) or blood pressure at Screening as defined in the protocol~* Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and CYP3A4 including fruit juices or beverages containing these substances~* History of prior mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or progression of disease on MEK inhibitors~* Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of RVO~* Life expectancy of less than 12 weeks~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pimasertib Capsule/Pimasertib Tablet (Type: EXPERIMENTAL): None
- Pimasertib Tablet/Pimasertib Capsule (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).